In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
Bauer G, Dao MA, Case SS, Meyerrose T, Wirthlin L, Zhou P, Wang X, Herrbrich P, Arevalo J, Csik S, Skelton DC, Walker J, Pepper K, Kohn DB, Nolta JA.
Bauer G, et al.
Mol Ther. 2008 Jul;16(7):1308-15. doi: 10.1038/mt.2008.93. Epub 2008 May 6.
Mol Ther. 2008.
PMID: 18461052
Free PMC article.